Compass Pathways' Comp360 Trial Yields 39% Depression Reduction, Seeks FDA Review
Compass Pathways' synthetic psilocybin formulation Comp360 passed a second large-scale trial, with 39% of participants experiencing clinically meaningful depression reduction at six weeks and no safety issues. The company has requested an FDA review meeting for potential approval, driving a 24% share gain over the past five days.
1. Clinical Trial Results
Compass Pathways’ synthetic psilocybin formulation Comp360 achieved statistically significant outcomes in two large-scale trials, with 25% of participants in the initial study and 39% in the follow-up reporting clinically meaningful depression reduction after six weeks.
2. Safety and Tolerability
Comp360 was generally well-tolerated across both trials, and no significant safety issues emerged, supporting its potential use in treatment-resistant depression.
3. FDA Review Steps
The company has formally requested a meeting with the Food and Drug Administration to outline its review process for Comp360, positioning the therapy for potential approval pending regulatory assessment.
4. Stock Performance
Investor optimism has driven Compass Pathways shares up 24% over the past five days as the trials' success and FDA submission raised prospects for market entry.